As the Biden Administration looked to transition COVID-19 policies, including flexibilities enabled by the COVID-19 emergency declarations, into improving standards of care for patients, it allowed the Public Health Emergency (PHE) Act to expire on May 11, 2023. Precision's Christy Banach considers how the end of the PHE Act will impact care delivery and patient care now that certain provisions that allowed for expanded, easier access to care may or may not remain in place.

LEARN MORE

We're honored to announce that PRECISIONvalue ranked in MM+M's Top 100 North American healthcare agencies of 2023.

LEARN MORE

As an increasing number of cell and gene therapies are US Food and Drug Administration approved, health care stakeholders are attempting to strike a balance between patient access to innovative treatments and overall affordability. Read about the survey by Precision's Erin Lopata, Christopher Terrone and Ami Gopalan to understand how access decision-makers and employers are using innovative financial models to support coverage of high-investment medications.

LEARN MORE

The Inflation Reduction Act will shift formulary development and contracting dynamics. Time for manufacturers to have a clear, persuasive value story. Learn more from PRECISIONvalue expert Erin Lopata.

LEARN MORE

Patients already look beyond their prescription benefits for ways to pay. The Inflation Reduction Act is likely to increase demand for new solutions. PRECISIONvalue Chief Medical Officer Dominic Galante explains why.

LEARN MORE

When you squeeze a balloon, the air goes somewhere. Same with the cost of drugs. PRECISIONvalue expert Andrew Cournoyer explains the anticipated fallout from the Inflation Reduction Act in this free report.

LEARN MORE

The Inflation Reduction Act (IRA) of 2022 contains a number of health care provisions, including those that will cut Medicare drug spending by an estimated $287 billion over 10 years, according to the congressional budget office. Some of the most widely discussed changes are several near-term changes to the Medicare Part D benefit that are some of the most significant changes in Medicare regulation since the Medicare Modernization Act of 2003. In this free brief (part 2 of 5), PRECISIONvalue expert Ryan Cox outlines how these cuts may impact access and affordability for all.

LEARN MORE